[
  {
    "ts": null,
    "headline": "Genmab A/S: Circling Back On This Complicated Story",
    "summary": "Genmab A/S shares dropped 25% despite positive data and acquisition of ProfoundBio. Click for my updated look at GMAB stock prospects.",
    "url": "https://finnhub.io/api/news?id=0297f49b63cdcfda69bf3a1f6304240a305d8a14e60f2c6559ce19d0f6f6ee78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734102652,
      "headline": "Genmab A/S: Circling Back On This Complicated Story",
      "id": 131971273,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Genmab A/S shares dropped 25% despite positive data and acquisition of ProfoundBio. Click for my updated look at GMAB stock prospects.",
      "url": "https://finnhub.io/api/news?id=0297f49b63cdcfda69bf3a1f6304240a305d8a14e60f2c6559ce19d0f6f6ee78"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Down 15.5% Year to Date: How to Play the Stock?",
    "summary": "REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.",
    "url": "https://finnhub.io/api/news?id=645dcdf5a0b5a36291a1e22bb47c971c325935ef8ea2f36acf2ed803f79a7bf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734098940,
      "headline": "Regeneron Down 15.5% Year to Date: How to Play the Stock?",
      "id": 131967662,
      "image": "https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.",
      "url": "https://finnhub.io/api/news?id=645dcdf5a0b5a36291a1e22bb47c971c325935ef8ea2f36acf2ed803f79a7bf0"
    }
  },
  {
    "ts": null,
    "headline": "Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge",
    "summary": "Roche’s Vabysmo is now available in prefilled syringes and vials for three retinal conditions.",
    "url": "https://finnhub.io/api/news?id=9bce5362913ec316994ac6b4492a230978176ca33980241db04d895ae013dce6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734092384,
      "headline": "Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge",
      "id": 131964839,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_1966737424.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Roche’s Vabysmo is now available in prefilled syringes and vials for three retinal conditions.",
      "url": "https://finnhub.io/api/news?id=9bce5362913ec316994ac6b4492a230978176ca33980241db04d895ae013dce6"
    }
  },
  {
    "ts": null,
    "headline": "American Century Focused Dynamic Growth Fund Q3 2024 Commentary",
    "summary": "The broad U.S. stock market posted solid gains that saw a reversal of trends from the first half of the year. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=de1a9e3597b99763ff340611ce4c76539e433699021b7f08351ac79069fef323",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734072300,
      "headline": "American Century Focused Dynamic Growth Fund Q3 2024 Commentary",
      "id": 131963716,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358927461/image_1358927461.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "The broad U.S. stock market posted solid gains that saw a reversal of trends from the first half of the year. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=de1a9e3597b99763ff340611ce4c76539e433699021b7f08351ac79069fef323"
    }
  }
]